Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
60results about How to "Inhibition of proliferation rate" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Carotenoid ester analogs or derivatives for controlling connexin 43 expression
InactiveUS20050009788A1Increase connexin expressionAmeliorate proliferationBiocideHydrocarbon active ingredientsSynthetic analogueCancer cell
A method of controlling (e.g., influencing or affecting) connexin 43 expression in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. In some embodiments, controlling connexin 43 expression in a subject may effectively treat cardiac arrhythmia and / or cancerous and pre-cancerous cells in a subject. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ester functionality.
Owner:CARDAX PHARMA
Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
InactiveUS20050009758A1Inhibit and ameliorate some typeMaintain relatively stableBiocideHydrocarbon active ingredientsDiseaseChemical compound
A method for inhibiting and / or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and / or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals. In some embodiments, the invention may include a chemical compound including an at least partially water soluble carotenoid analog or derivative. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ether functionality.
Owner:CARDAX PHARMA
Carotenoid ether analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
InactiveUS20050065097A1Inhibit and ameliorate some typeMaintain relatively stableAntibacterial agentsOrganic active ingredientsSynthetic analogueAntioxidant
A method of treating ischemic reperfusion injury in a subject. The method may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ether functionality.
Owner:CARDAX PHARMA
Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
InactiveUS20050090469A1Increase connexin expressionAmeliorate proliferationBiocideHydrocarbon active ingredientsSynthetic analogueDisease
A method of treating liver disease in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ester functionality.
Owner:CARDAX PHARMA
Pharmaceutical compositions including carotenoid analogs or derivatives for the inhabition and amelioration of disease
InactiveUS20050075337A1Inhibit and ameliorate some typeMaintain relatively stableAntibacterial agentsOrganic active ingredientsSolubilityDouble bond
Owner:CARDAX PHARMA
Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
InactiveUS20050049248A1Increase connexin expressionAmeliorate proliferationBiocideHydrocarbon active ingredientsSynthetic analogueAntioxidant
A method of controlling (e.g., influencing or affecting) C-reactive protein levels in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one j e substituent. The substituent may be coupled to the cyclic ring with an ether functionality.
Owner:CARDAX PHARMA
Carotenoid analogs or derivatives for controlling connexin 43 expression
InactiveUS20050009930A1Inhibit and ameliorate some typeMaintain relatively stableBiocideHydrocarbon active ingredientsSynthetic analogueDouble bond
A method of controlling (e.g., influencing or affecting) connexin 43 expression in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. In some embodiments, controlling connexin 43 expression in a subject may effectively treat cardiac arrhythmia and / or cancerous and pre-cancerous cells in a subject. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and / or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent.
Owner:CARDAX PHARMA
Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
InactiveUS20050065096A1Increase connexin expressionAmeliorate proliferationBiocideHydrocarbon active ingredientsDiseaseEther
A method for inhibiting and / or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and / or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals. In some embodiments, the invention may include a pharmaceutical composition including a carotenoid analog or derivative. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ether functionality. In some embodiments, a pharmaceutical composition may include a biologically inactive carrier. The pharmaceutical composition may be adapted to be administered to a human subject.
Owner:CARDAX PHARMA
Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
InactiveUS20050059635A1Increase connexin expressionAmeliorate proliferationBiocideHydrocarbon active ingredientsSynthetic analogueAntioxidant
A method of controlling (e.g., influencing or affecting) C-reactive protein levels in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ester functionality.
Owner:CARDAX PHARMA
Carotenoid analogs or derivatives for the inhibition and amelioration of disease
InactiveUS7521584B2Ameliorate some typeMaintain relatively stableBiocideHydrocarbon active ingredientsDiseaseSolubility
A method for inhibiting and / or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and / or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals. In some embodiments, the invention may include a chemical compound including an analog or derivative of a carotenoid. The carotenoid analog or derivative may be synthetic. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and / or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent. The substituent may enhance the solubility of the carotenoid analog or derivative such that the carotenoid analog or derivative at least partially dissolves in water.
Owner:CARDAX PHARMA
Application of PNO1 inhibitor to preparation of esophagus cancer treatment medicines
ActiveCN110656111AInhibition of proliferation rateInhibition of clonogenicityFermentationAntineoplastic agentsCell invasionPharmaceutical drug
The invention relates to an application of a PNO1 inhibitor to preparation of esophagus cancer treatment medicines, belongs to the field of biopharmaceutical research, and particularly relates to an application of a PNO1 inhibitor to preparation of esophagus cancer treatment medicines. The inventor firstly finds that the PNO1 can be used as an esophagus cancer treatment target point. The PNO1 inhibitor can restrain the proliferation rate of esophagus cancer cells, can restrain the cloning and forming capacity of the esophagus cancer cells, can promote esophagus cancer apoptosis, can restrain esophagus cancer cell migration, can restrain esophagus cancer cell transfer, and can restrain esophagus cancer cell invasion and transfer, so as to treat esophagus cancer, and a new direction is opened up for treatment of esophagus cancer.
Owner:THE FIRST AFFILIATED HOSPITAL OF BENGBU MEDICAL COLLEGE
Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
InactiveUS7723327B2Ameliorate some typeMaintain relatively stableBiocideHydrocarbon active ingredientsSynthetic analogueDisease
Owner:CARDAX PHARMA
Iodine-enriched seaweed fertilizer and manufacturing method thereof
InactiveCN101265139AAvoid poisoning accidentsLong durationFertilizer mixturesFertilizerNutrient deficiency
The invention discloses a fertilizer, in particular an iodine accumulation seaweed fertilizer and a manufacture method thereof. The iodine accumulation seaweed fertilizer has the special aspects that the iodine accumulation seaweed fertilizer is a solid preparation made of the material and auxiliary materials by weight parts as follows: iodine is 1 to 35 parts, benzoate is 110 to 160 parts, compound sodium nitrophenolate is 1 to 8 parts, alcohol is 300 to 800 parts, water is 60 to 120 parts, and alkali is 1 to 2 parts. The solid preparation is granula, which has the particle size range that the diameter ranges from 2 to 3mm. The iodine accumulation seaweed fertilizer effectively improves the root environments of planting crops, and restrains the proliferation rate and the survival rate of nematodes, thereby restricting the quantity and the epidemic degree of the nematodes and promoting the well-developed root system of the planting crops. The iodine accumulation seaweed fertilizer not only provides microelement nutrition to the nutrient deficiency of plants, but also has restraining and repellent effects on the root knot nematode, and is the ideal preparation for producing harmless agricultural products.
Owner:沈刚
Application of small-molecular citrus pectin
InactiveCN104873533AImprove the level ofRegulate immune cell differentiationOrganic active ingredientsAntineoplastic agentsCitrus PectinEfficacy
The invention discloses a new application of small-molecular citrus pectin. The small-molecular citrus pectin can be used for preparing anti-tumor auxiliary medicines which have immunoregulation effects and can be used for cooperating with the effect-enhancing and toxicity-reducing action of chemotherapy medicines, or can be used for preparing health products with anti-tumor auxiliary effects. A compound disclosed by the invention cannot be used for directly killing tumor cells when being separately used, and does not have anti-tumor effects; the compound can be taken as an auxiliary medicine, can cooperate with the chemotherapy medicines for use, can have immunoregulation functions on T cells and MDSC cells by virtue of ligands on the surfaces of antagonistic immune cells and tumor tissue cells of the compound, can be used for enhancing the anti-tumor effects in an auxiliary mode, and ensures that the sensitivity-enhancing and toxicity-reducing effects on tumor chemotherapy can be achieved; and new medical applications of the known compound namely the small-molecular citrus pectin can be explored, and a new application field can be created.
Owner:ZHEJIANG UNIV
Application of aspirin in preparing medicine for treating NSCLC (non-small cell lung cancer)
InactiveCN108096257AOvercoming acquired drug resistanceIncreased sensitivityOrganic active ingredientsAntineoplastic agentsAspirinOncology drugs
The invention belongs to the field of antitumor drugs and specifically discloses application of aspirin in preparing medicine for treating NSCLC (non-small cell lung cancer). In comparison with the fact that osimertinib is applied alone to treat EGFR(+) NSCLC, the drug combination of the aspirin and the osimertinib can effectively inhibit proliferation of the EGFR(+) NSCLC cells, so as to promoteapoptosis of the EGFR(+) NSCLC cells. The drug combination of the aspirin and the osimertinib enhances sensitivity of the NSCLC patient to EGFR-TKI, overcomes the defect of highly possible drug resistance to the osimertinib, increases the effective treatment time of the osimertinib and can further improve the prognosis of the EGFR(+) NSCLC patient.
Owner:THE THIRD AFFILIATED HOSPITAL INST OF FIELD SURGERY OF PLA ARMY MEDICAL UNIV
Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
InactiveUS7345091B2Ameliorate some typeMaintain relatively stableBiocideHydrocarbon active ingredientsChemical compoundEther
A method for inhibiting and / or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals may be thereby reduced. In some embodiments, the invention may include a chemical compound including an at least partially water soluble carotenoid analog or derivative. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. The substituent may be coupled to the cyclic ring with an ether functionality.
Owner:CARDAX PHARMA
Use of human GSDMB gene and related products
ActiveCN110917357APrevent proliferationInhibit apoptosisOrganic active ingredientsFermentationSlow Virus DiseasesNucleic acid
The invention belongs to the field of researches on biomedicines and particularly relates to use of a human GSDMB gene in preparation of urinary bladder carcinoma treatment drugs as a target. According to the use of the human GSDMB gene and the related products, discovered by extensive and deep-going researches, through lowering expression of the human GSDMB gene by employing an RNAi method, the propagation of urinary bladder carcinoma cells can be effectively inhibited, apoptosis can be effectively promoted, and a growth process of a urinary bladder carcinoma can be effectively controlled. AnsiRNA provided by the invention or an siRNA sequence containing nucleic acid construct and slow virus can be used for specifically inhibiting a rate of propagation of the urinary bladder carcinoma cells, promoting the apoptosis of the urinary bladder carcinoma cells, inhibiting transferring of the urinary bladder carcinoma cells, inhibiting invasion of the urinary bladder carcinoma cells and inhibiting growth of the urinary bladder carcinoma so as to treat the urinary bladder carcinoma, and thus, a new direction is opened up for urinary bladder carcinoma treatment.
Owner:THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV
Application of RSPH14 gene, application of RSPH14 inhibitor, nucleic acid molecule, construct and composition
PendingCN111349701APrevent proliferationInhibit apoptosisOrganic active ingredientsMicrobiological testing/measurementCancer cellPharmaceutical drug
The invention belongs to the field of biological medicine research, and specifically relates to an application of a human RSPH14 gene as a target in preparation of a lung cancer treatment drug or a lung cancer diagnosis drug. According to the invention, results of wide and deep research find that effective inhibition to proliferation of lung cancer cells, promotion of apoptosis and effective control to the growth process of the lung cancer can be realized after the expression of the human RSPH14 gene is down-regulated by adopting an RNAi method. The siRNA or the nucleic acid construct and theslow virus containing the siRNA sequence provided by the invention can specifically inhibit the proliferation rate of the lung cancer cells, influence the cycle of the lung cancer cells, promote apoptosis of the lung cancer cells and inhibit the growth of the lung cancer, so the lung cancer is treated, and a new direction is opened up for treatment of the lung cancer.
Owner:SICHUAN CANCER HOSPITAL
Application of benzisoselenazole derivative combined with platinum drug to preparation of tumor treatment drugs and postoperative tumor recurrence drugs
PendingCN110856718APrevent proliferationInhibition of proliferation rateHeavy metal active ingredientsAntineoplastic agentsCarboplatinTumor therapy
The invention belongs to the technical field of tumor treatment, and discloses application of a benzisoselenazole derivative combined with a platinum drug to the preparation of tumor treatment drugs and postoperative tumor recurrence drugs. The benziselenazole derivative has a structure as shown in the formula A, the platinum-based anticancer drug is selected from at least one of cisplatin, carboplatin, oxaliplatin, nedaplatin, and the like. The molar ratio of the benziselenazole derivative to the platinum-based anticancer drug is (1-99): (1-99). With the combination of the benzisoselenazole derivative and the platinum drug, the dosage of platinum-based anticancer drug with high toxicity can be effectively reduced and the safety of anticancer drugs can be improved; and Bel-7402 cell apoptosis can be induced by reducing Bcl-2 / Bax protein expression ratio, and the expression of TrxR in tumor tissues can be synergistically inhibited, the proliferation rate of tumor cells after operation can be significantly reduced, and the growth inhibition rate of tumor cells after operation can be improved.
Owner:SHANGHAI YUANXI MEDICINE CORP
Purpose of KIF15 inhibitor to preparation of liver cancer treatment medicine
InactiveCN107789624AInhibition of proliferation rateGrowth inhibitionMicrobiological testing/measurementAntineoplastic agentsMultiplication rateApoptosis
The invention belongs to the field of biological medicine study, and particularly relates to a purpose of a KIF15 inhibitor. Through wide and deep study, the condition that the KIF15 can be used as alung cancer treatment target point is discovered for the first time. The KIF15 inhibitor can achieve the effects of inhibiting the multiplication rate of the lung cancer cells, changing the lung cancer cell period distribution, promoting the lung cancer cell apoptosis and inhibiting the lung cancer tissue growth, so that the lung cancer can be treated; a new direction can be opened for the lung cancer treatment.
Owner:JILIN UNIV
Prawn feed additive and application thereof
InactiveCN105724826AReduce mortalityPrevent proliferationAccessory food factorsAnimal scienceArginine
The invention provides a prawn feed additive and application thereof, and relates to a feed additive.The prawn feed additive is L-arginine and has the Chinese nicknames of arginine, L-2-amino-5-guanidinovaleric acid, guanidinovaleric acid and L-guanidinovaleric acid; the molecular formula of L-arginine is C6H14N4O2; the molecular weight of L-arginine is 174.20.The prawn feed additive can be applied to preparation of feed for resisting a prawn white spot syndrome virus.The prawn feed additive L-arginine is added into prawn feed to be premixed and then dried at the temperature of 50 DEG C-60 DEG C, and then the feed for resisting the prawn white spot syndrome virus is obtained.Through experiments, it is verified that the death rate of prawns attacked by the white spot syndrome virus can be effectively decreased by adding L-arginine in the feed, and the multiplication speed of the prawn white spot syndrome virus in prawn bodies can be significantly inhibited by injecting L-arginine.
Owner:JIMEI UNIV
Application of isoflavone compound Final-2 in preparing glucose transporter expression inhibitor of lung cancer cells
ActiveCN110368380AInhibition of proliferation rateArrest cycle growthOrganic active ingredientsAntineoplastic agentsCancer cellIsoflavonoid
Owner:JINAN UNIVERSITY
Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
InactiveUS7320997B2Ameliorate some typeMaintain relatively stableBiocideHydrocarbon active ingredientsDiseaseDouble bond
A method for inhibiting and / or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals may be thereby reduced. In some embodiments, the invention may include a pharmaceutical composition including a carotenoid analog or derivative. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. The substituent may be coupled to the cyclic ring with an ester functionality. The pharmaceutical composition may be adapted to be administered to a human subject.
Owner:CARDAX PHARMA
Serum-free culture solution for in-vitro culture of sheep ovarian cortex tissue
InactiveCN112458041AMeet basic growth needsInhibition of proliferation rateCell dissociation methodsCulture processPenicillinGranular cell
The invention discloses a serum-free culture solution for in-vitro culture of sheep ovarian cortex tissue. The culture solution comprises a basic culture solution and an additive, wherein the basic culture medium is a mixed solution of alpha-MEM and DMEM; the additive comprises the following components: 3-10 micrograms / mL bovine serum albumin, 0.10-0.50mM sodium pyruvate, 1-5mM glutamine, 1-5mM hypoxanthine, 3-10 micrograms / mL insulin, 1-5 micrograms / mL transferrin, 2-8 nanograms / mL sodium selenite, 10-200 micrograms / mL VC, 50-200IU / mL penicillin and 50-200IU / mL streptomycin, and the pH valueis 6.9-7.5. Through the synergistic effect of the components, the proliferation speed of interstitial cells is inhibited, the proliferation of granular cells is promoted, the defect that the three-dimensional environment of original follicle development cannot be maintained due to tissue collapse caused by excessive proliferation of the interstitial cells in the culture process of the ovarian cortex tissue is overcome, the growth and development condition and survival time of original follicles in the ovarian cortex tissue in vitro are effectively improved, meanwhile, the influence of unknowncomponents in serum on research is avoided, and the serum-free culture solution has a good application prospect.
Owner:SHIHEZI UNIVERSITY
Application of human HIST1H2BK gene and related products
PendingCN110904104APrevent proliferationInhibit apoptosisOrganic active ingredientsMicrobiological testing/measurementCancer cellApoptosis
The invention belongs to the field of biomedical research, and particularly relates to application of human HIST1H2BK gene as a target in preparation of drugs used for treating liver cancer. It is found through wide and deep research that proliferation of liver cancer cells can be effectively inhibited, apoptosis can be promoted and the growth process of liver cancer can be effectively controlledafter the expression of human HIST1H2BK gene is down-regulated by adopting an RNAi method. A siRNA provided by the invention, or a nucleic acid construct and lentivirus containing the siRNA sequence can specifically inhibit the proliferation rate of liver cancer cells, promote apoptosis of liver cancer cells, inhibit cloning of liver cancer cells and inhibit growth of liver cancer cells, so that liver cancer is treated, and a new direction is provided for liver cancer treatment.
Owner:广西医科大学附属肿瘤医院
MiR-517a-3p related to cisplatin resistance of tumor cells and application of miR-517a-3p
ActiveCN112359115AInhibition of proliferation rateInhibition of clonogenicityOrganic active ingredientsInorganic active ingredientsCancer cellTreatment targets
The invention discloses miR-517a-3p related to cisplatin resistance of tumor cells and an application of the miR-517a-3p. The invention also discloses a kit for detecting the drug resistance degree oftumor cells to cisplatin. According to the miR-517a-3p, by establishing an SK-OV-3 / DDP drug-resistant cell strain, it is found that miR-517a-3p can be used as a marker of drug resistance of tumor cells; the miR-517a-3p plays a certain role in the drug resistance of the SK-OV-3 / DDP cells to the DDP, and the drug resistance of the SK-OV-3 / DDP cells to the DDP can be reversed by down-regulating themiR-517a-3p; in addition, the proliferation speed of ovarian cancer SK-OV-3 / DDP cells can be inhibited, and meanwhile, the cloning formation capability of the ovarian cancer SK-OV-3 / DDP cells is alsoinhibited. The miR-517a-3p is advantaged in that a scientific basis is provided for searching a new molecular treatment target, guiding clinical medication and more effectively resisting cisplatin resistance.
Owner:河北仁博科技有限公司
Application of S-methylisothiourea sulfate in preparation of anti-influenza virus and escherichia coli co-infection drugs
InactiveCN112755012AInhibition of proliferation rateReduce loadAntibacterial agentsAntiviralsEscherichia coliVirus
The invention discloses application of S-methylisothiourea sulfate in preparation of anti-influenza virus and escherichia coli co-infection drugs. Experiments prove that at the cellular level, the compound S-methylisothiourea sulfate can significantly inhibit proliferation of escherichia coli under the condition of mixed infection; at the animal level, after S-methylisothiourea sulfate (20mg / kg / mouse) is dropped into a mouse in a nasal dropping mode, the resistance of the mouse to H9N2 subtype influenza virus and escherichia coli mixed infection is enhanced, the survival rate of the mouse infected with H9N2 subtype influenza virus and escherichia coli is increased compared with that of a mouse infected with H9N2 subtype influenza virus and escherichia coli without dropping S-methylisothiourea sulfate, and the carrying capacity of influenza virus and escherichia coli in the lung is obviously reduced. The compound is effectively applied to resisting influenza virus and escherichia coli mixed infection, can serve as a new candidate drug for resisting influenza virus and escherichia coli mixed infection, and provides more choices for treatment of influenza virus and escherichia coli mixed infection clinically.
Owner:FUJIAN AGRI & FORESTRY UNIV
Application and correlation product of human IMPA2 gene
InactiveCN110938692APrevent proliferationInhibit apoptosisOrganic active ingredientsHydrolasesApoptosisOncology
The invention belongs to the field of biopharmaceutical research, and particularly relates to an application of a human IMPA2 gene as a target to preparation of drugs for treating cervical cancer or drugs for diagnosis of cervical cancer. Through wide and deep research, the inventor finds that after an RNAi method is adopted for reducing the expression of the human IMPA2 gene, proliferation of cervical carcinoma cells can be effectively restrained, apoptosis is promoted, and growth process of the cervical cancer can be effectively controlled. siRNA or a nucleic acid constructor containing thesiRNA sequence, and a slow virus provided by the invention can specially restrain proliferation rate of the cervical carcinoma cells, can promote the apoptosis of the cervical carcinoma cells, can restrain cloning of the cervical carcinoma cells, can influence the period of the cervical carcinoma cells, and can restrain growth of the cervical cancer, so as to treat the cervical cancer and open upa new direction for treatment of the cervical cancer.
Owner:THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV
Carotenoid analogs or derivatives for controlling connexin 43 expression
InactiveUS7763649B2Ameliorate some typeMaintain relatively stableBiocideHydrocarbon active ingredientsAntioxidantDouble bond
A method of controlling (e.g., influencing or affecting) connexin 43 expression in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. In some embodiments, controlling connexin 43 expression in a subject may effectively treat cardiac arrhythmia and / or cancerous and pre-cancerous cells in a subject. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and / or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent.
Owner:CARDAX PHARMA
Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
InactiveUS7375133B2Ameliorate some typeMaintain relatively stableBiocideHydrocarbon active ingredientsEtherDouble bond
A method for inhibiting and / or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and / or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals. In some embodiments, the invention may include a pharmaceutical composition including a carotenoid analog or derivative. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ether functionality. In some embodiments, a pharmaceutical composition may include a biologically inactive carrier. The pharmaceutical composition may be adapted to be administered to a human subject.
Owner:CARDAX PHARMA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com